Daniel Swisher
Equibles does not estimate personal net worth.
About Daniel Swisher
Earlier roles on record: COO at Jazz Pharmaceuticals plc (JAZZ) until March 31, 2024 and COO at Jazz Pharmaceuticals plc (JAZZ) until October 1, 2023. Jazz Pharmaceuticals plc reported in an 8-K filed September 12, 2023 that Daniel Swisher retired as President and Chief Operating Officer, effective March 31, 2024. The proxy statement of Jazz Pharmaceuticals plc reports total compensation of $5,528,973 for Daniel Swisher in fiscal 2023, including a base salary of $834,869. Disclosed compensation is on record for 6 fiscal years. Daniel Swisher has spoken on 2 earnings calls across 1 company, most recently for Jazz Pharmaceuticals plc on May 10, 2023. The companies whose calls Daniel Swisher spoke on are classified in the Healthcare sector.
“On September 6, 2023, Daniel Swisher, Jr., President and Chief Operating Officer of Jazz Pharmaceuticals plc ("Jazz" or the "Company"), informed the Company of his intention to retire from the Company, effective March 31, 2024 (the "Retirement Date").”
Daniel Swisher on recent calls
“I'm excited to share the continued progress across our commercial portfolio. I'll begin on Slide 8 with neuroscience and our oxybate franchise. We remain confident in the durability of our oxybate franchise and have established low sodium Xywav as the oxybate treatment of choice.”
“I'm excited to share the progress across our commercial portfolio. I want to begin with neuroscience on slide 7 and 8 and first discuss our combined oxybate franchise, including Xyrem and Xywav.”
Affiliation history
-
Jazz Pharmaceuticals plc (JAZZ)
Proxy statement
Start not stated–2022-06-13
Last confirmed by a filing; no departure on record
-
Start not stated–2023-10-01
-
Start not stated–2024-03-31
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Jazz Pharmaceuticals plc (JAZZ) | Former President and COO | $834,869 | $5,528,973 |
| 2022 | Jazz Pharmaceuticals plc (JAZZ) | Former President and COO | $801,433 | $5,953,745 |
| 2021 | Jazz Pharmaceuticals plc (JAZZ) | Former President and COO | $711,154 | $5,403,892 |
| 2020 | Jazz Pharmaceuticals plc (JAZZ) | President, COO | $713,654 | $4,471,087 |
| 2019 | Jazz Pharmaceuticals plc (JAZZ) | President | $667,308 | $4,707,407 |
| 2018 | Jazz Pharmaceuticals plc (JAZZ) | President and COO | $608,173 | $5,753,341 |